Across TCGA pan-cancer cohorts, NFYBP1 RNA is linked to patient survival in 21 of 34 cancer types, making it the most broadly survival-associated NFYBP1 data layer.
The strongest signal is observed in mesothelioma (MESO), where higher NFYBP1 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated NFYBP1 expression acts as an unfavorable survival marker, although some lineages such as CESC and SKCM show a favorable association.
MESO, THYM, and COAD are the cancer types where NFYBP1 RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.